Third patient implanted with Ventracor device
Thursday, 23 October, 2003
Ventracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
According to the chief medical investigator Prof Don Esmore, the patient is in a critical but stable condition.
He said the patient was gravely ill at the time of the procedure, and the implant was the only option available.
The announcement comes a couple of weeks after the second patient to receive the implant was discharged from hospital. The company plans to test up to ten patients in the pilot trial, before embarking on a larger, international trial.
Ventracor's share price rose four per cent yesterday after the announcement was made to close at AUD$2.49.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
